Reference health

Towards a population-based threshold of protection for COVID-19 vaccines

https://doi.org/10.1016/j.vaccine.2021.12.006
CiteStamped reference-health badge
21/21 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 21 checked references that resolve
resolves10.1038/s41591-021-01377-8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
resolves10.1016/j.vaccine.2021.05.063
Evidence for antibody as a protective correlate for COVID-19 vaccines
resolves10.1128/CVI.00131-10
Correlates of Protection Induced by Vaccination
resolves10.1093/infdis/162.5.1036
Measles Antibody: Reevaluation of Protective Titers
resolves10.3390/vaccines7040158
Additional Evidence on Serological Correlates of Protection against Measles: An Observational Cohort Study among Once Vaccinated Children Exposed to Measles
resolves10.1084/jem.129.6.1307
HUMAN IMMUNITY TO THE MENINGOCOCCUS
resolves10.1038/s41591-021-01540-1
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
resolves10.1016/j.vaccine.2007.01.119
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
resolves10.1016/S0264-410X(03)00230-5
Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants
resolves10.1093/ofid/ofaa555
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
resolves10.1016/S0140-6736(21)00527-4
WHO International Standard for anti-SARS-CoV-2 immunoglobulin
resolves10.1016/j.chom.2020.06.021
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
resolves10.1038/s41587-020-0631-z
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
resolves10.1136/bmj.n1875
Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds
resolves10.1056/NEJMoa2109072
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
resolves10.1016/j.jhin.2020.12.019
Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries
resolves10.1016/j.jcv.2020.104572
Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2
resolves10.1056/NEJMc2101667
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
resolves10.1016/j.chom.2021.03.002
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
resolves10.1080/02664769922458
Calculating nonparametric confidence intervals for quantiles using fractional order statistics
resolves10.15585/mmwr.mm7020e2
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021
The 9 references without a DOI — listed, not checked
no DOI — not checkedImmune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
no DOI — not checkedMethods for estimating serological correlates of protection
no DOI — not checkedValidation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
no DOI — not checkedLow Dose Regimens of BNT162b2 mRNA Vaccine Exceed SARS-Cov-2 Correlate of Protection Estimates for Symptomatic Infection, in those 19–55 Years of Age
no DOI — not checkedCorrelates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
no DOI — not checkedBNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2
no DOI — not checkedImmunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compated With 4 Approved Vaccines
no DOI — not checkedProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel
no DOI — not checkedReduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1016/j.vaccine.2021.12.006"><img src="https://citestamp.com/citestamped/10.1016/j.vaccine.2021.12.006/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1016/j.vaccine.2021.12.006/badge.svg)](https://citestamp.com/citestamped/10.1016/j.vaccine.2021.12.006)